Vocal aging and adductor spasmodic dysphonia: Response to botulinum toxin injection by Cannito, Michael P et al.
© 2008 Dove Medical Press Limited.   All rights reserved
Clinical Interventions in Aging 2008:3(1) 131–151 131
REVIEW
Vocal aging and adductor spasmodic dysphonia: 
Response to botulinum toxin injection
Michael P Cannito
Joel C Kahane
Lesya Chorna
School of Audiology and Speech-
Language Pathology, The University
of Memphis, Memphis, TN, USA
Correspondence: Michael P Cannito
School of Audiology and Speech-Language 
Pathology, The University of Memphis, 807 
Jefferson Avenue, Memphis, TN 38105, 
USA
Tel +1 901 678 5800
Fax +1 901 525 1282
Email mcannito@memphis.edu
Abstract: Aging of the larynx is characterized by involutional changes which alter its 
biomechanical and neural properties and create a biological environment that is different from 
younger counterparts. Illustrative anatomical examples are presented. This natural, non-disease 
process appears to set conditions which may inﬂ  uence the effectiveness of botulinum toxin 
injection and our expectations for its success. Adductor spasmodic dysphonia, a type of laryn-
geal dystonia, is typically treated using botulinum toxin injections of the vocal folds in order 
to suppress adductory muscle spasms which are disruptive to production of speech and voice. 
A few studies have suggested diminished response to treatment in older patients with adductor 
spasmodic dysphonia. This retrospective study provides a reanalysis of existing pre-to-post treat-
ment data as function of age. Perceptual judgments of speech produced by 42 patients with ADSD 
were made by two panels of professional listeners with expertise in voice or ﬂ  uency of speech. 
Results demonstrate a markedly reduced positive response to botulinum toxin treatment in the 
older patients. Perceptual ﬁ  ndings are further elucidated by means of acoustic spectrography. 
Literature on vocal aging is reviewed to provide a speciﬁ  c set of biological mechanisms that best 
account for the observed interaction of botulinum toxin treatment with advancing age.
Keywords: vocal aging, adductor spasmodic dysphonia, botulinum toxin, voice quality, speech 
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Introduction
Phonatory function is known to decline as a result of normal aging due to changes in the 
viscoelastic properties of the vocal folds along with other laryngeal biomechanical and 
neurologic changes (Kahane 1996). Moreover, movement disorders that tend to be more 
prevalent in older individuals (eg, Parkinson’s disease) also tend to negatively impact 
phonatory ability. The relationship between normal aging and co-occurring voice 
disorders, and particularly the impact of vocal aging on treatment of voice disorders, has 
not been well studied. One such movement disorder is adductor spasmodic dysphonia 
(ADSD), a type of focal laryngeal dystonia that impedes voice production and usually 
has debilitating effects on speech communication. ADSD affects laryngeal function 
in adults throughout the lifespan. This review examines the voice disorder of ADSD 
and the effect of vocal aging on its response to a speciﬁ  c treatment, botulinum toxin 
(BT) injection of the vocal folds. In addition, a retrospective reanalysis of recently 
published data consisting of expert listeners’ perceptual ratings of ADSD speakers 
before and after BT injection is provided to further examine the inﬂ  uence of aging 
on treatment outcome.
Adductor spasmodic dysphonia
Adductor spasmodic dysphonia (ADSD) is an uncommon voice disorder characterized 
by intermittent voice stoppages, or breaks in voicing associated with over adduction 
of the vocal folds, resulting in a “strained-strangled” voice quality, and disﬂ  uent, Clinical Interventions in Aging 2008:3(1) 132
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effortful speech production. These behaviors result from 
intermittent adductor spasms or squeezing of the vocal folds 
in the closed direction. ADSD is diagnostically differentiated 
from abductor spasmodic dysphonia (ABSD) in which 
the vocal folds spasm in the open direction, resulting in 
intermittent breathy dysphonia. ADSD also is diagnostically 
differentiated from dyasarthria, in which the muscles of 
articulation also exhibit movement abnormalities affecting 
speech, but with which it may co-occur. ADSD is typically 
regarded as a type of focal, action induced, laryngeal dystonia 
(Blitzer et al 1998). Central nervous system dysfunction 
in a number of supranuclear brain regions associated with 
laryngeal motor control have been implicated in the disorder, 
with support from a variety of neuroimaging techniques 
(Finitzo and Freeman 1989; Devous et al 1990; Haslinger 
et al 2005; Ali et al 2006); however, no speciﬁ  c locus of 
neurologic dysfunction or precipitating disease state has as 
yet emerged as an immediate causative explanation for the 
majority of persons with ADSD. ADSD is considered to be 
a relatively uncommon voice disorder; however, its precise 
incidence and prevalence remain unknown. It tends to affect 
women more frequently than men; however, sex ratios vary 
markedly from study to study. Onset typically occurs during 
middle age; but earlier and later onset ages have been reported 
in the literature (Aronson 1990). Following onset, there is 
typically a worsening of dysphonia over the ﬁ  rst six months 
to a year. Beyond that time, the voice disorder typically 
stabilizes and does not usually continue to deteriorate. 
Although the phonatory symptoms may co-occur with 
movement disorders elsewhere in the body (eg, dystonia or 
tremor of the neck or limbs), ADSD also frequently occurs as 
an isolated phenomenon, and may or may not be associated 
with laryngeal tremor.
Some common features of untreated ADSD (middle 
panels) and nondysphonic control voices (top panels) are 
illustrated in Figures 1 and 2, which provide acoustic spec-
trographic images or “voice prints.” Each panel is a visual 
representation of sound produced during vocalization of the 
phrases “… raindrops in the air …” (Figure 1) and “When 
the sunlight …” (Figure 2). Sound frequency is represented 
on the vertical axis (from 0 to 5 KHz), while elapsed time 
is represented on the horizontal axis. The phrase duration 
(msec) is provided in the lower right corner of each panel. 
Darkness of shading indicates sound intensity. A younger, 
38 year old female speaker with ADSD and her matched 
normal control are presented in Figure 1. Figure 2 presents 
an older, 74 year old female ADSD speaker with matched 
normal control.
Inspection of the top panels of Figures 1 and 2 reveal 
that the normal phrases were produced rapidly with smooth 
transitions between sounds, syllables and words. Voiced 
sounds such as vowels appear as vertical striations spread 
across the frequency range. Each striation represents one cycle 
of vocal fold vibration, occurring closely together in time 
at a rate of approximately 220 cycles per second. Voiceless 
sound, such as the /s/ in “sun” appears as a fuzzy or stippled 
feature in the higher frequency range in the absence of vertical 
striations. The only breaks in the normal ﬂ  ow of sound were 
brief silences (lack of shading less than 20 msec) before and 
after the voiceless /s/ sound in “sun.”
Prior to BT injection, the ADSD speakers (middle 
panels) exhibit dramatic prolongation of their phrases, taking 
more than twice as much time as their normal counterparts. 
ADSD productions also exhibit several voice breaks of long 
duration, during which the vocal folds are compressed tightly 
together (adductor spasms). It is notable that some voice 
breaks occur within vowels (eg, “su-un”), contributing to 
an overall impression of disﬂ  uency. Glottal stops occur as 
isolated vertical striations at moments when the adducted 
vocal folds were blown apart in an effort to reinitiate voicing. 
Strained-strangled voicing is characterized by widely and 
irregularly spaced vertical striations indicating slow and 
aperiodic vocal fold vibration.
BT injection of the vocal folds
Behavioral voice therapy has not proven effective for treating 
ADSD (Cannito and Woodson 2000). Despite a variety of 
surgical options (eg, sectioning of a recurrent laryngeal 
nerve), injection of the true vocal fold(s) with BT is now 
generally regarded as the preferred method of treatment 
(Cannito and Woodson 2000). BT injection weakens 
neuromuscular contraction of the vocal folds by interfering 
with release of acetylcholine (ACh) at the neuromuscular 
junction (NMJ). This induced partial paralysis reduces the 
effect of adductor spasms on voice production and, following 
a brief period of intense breathiness, beneﬁ  t may last up to 
three months, after which the effects of the toxin gradually 
subside and re-injection is necessary (Ludlow 1995). BT is 
typically delivered to the thyroaretenoid muscle (TA) of a 
vocal fold using transcutaneous injection through the neck, 
with needle placement veriﬁ  ed via electromyography (Miller 
et al 1987; Blitzer and Brin 1992). Alternatively, transoral or 
transnasal approach may be employed using nasoendoscopy 
for visual guidance (Ford et al 1992; Rhew et al 1994). 
Injections may also be either unilateral or bilateral, with 
little evidence supporting one method over the other, and Clinical Interventions in Aging 2008:3(1) 133
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dosages employed vary widely within and across studies 
(Boutsen et al 2002). The variation in dosage level reported 
by different clinicians is based, in part on the severity of 
presenting signs and symptoms, and/or whether the injection 
is unilateral or bilateral. It has been suggested that smaller 
dosages injected bilaterally may have a similar effect on 
voice production in ADSD as substantially larger unilateral 
dosages (Woodson 1994).
Efﬁ  cacy of BT injection for ADSD is well established 
(Truong et al 1991; Blitzer and Brin 1992; Boutsen et al 
2002). Following treatment there are fewer voice breaks and 
fewer episodes of strained strangled dysphonia, and pitch 
becomes more stable. Recent studies, however, also have 
demonstrated that even during post-injection periods when 
beneﬁ  t is considered optimal, both acoustic and perceptual 
indices continued to signiﬁ  cantly differentiate ADSD from 
control speakers (Langveldt et al 2001; Sapienza et al 2002; 
Cannito et al 2004). This was especially true of phonatory 
aperiodicity or “roughness” and “breathiness” present in 
both sustained vowels and connected speech. However, the 
effect of aging upon treatment outcome in ADSD has not 
been well studied.
Figures 1 and 2 (bottom panels) provide spectrograms 
of post-injection ADSD speech. It is apparent in Figure 1 
that, following BT injection, the younger speaker achieved 
an almost normal appearing production. Syllable timing 
is rapid, with smooth transitions between sounds and syl-
lables and vertical striations are narrowly and regularly 
spaced. The post treatment voice is mildly breathy and 
hoarse, however, as indicated by light stippling in the 
high frequency range overlaid upon the vertical striations 
for voiced sounds. This is due to air turbulence associ-
ated with slight weakness of the vocal folds following 
injection. In Figure 2, the older speaker’s post-injection 
production (bottom panel) is even slower than pre-injec-
tion (middle panel). Following injection, voice breaks and 
strain-strangled voice remain in evidence; however, high 
frequency stippling overlaid upon the vertical striations of 
vowel sounds indicates that the voice is also breathy due 
to BT-induced weakness.
Figure 1 Spectrograms of the phrase “… raindrops in the air …” spoken by a 38 year old female: normal control subject is depicted on the top panel, ADSD before BT 
injection is on the middle, and ADSD after BT injection is on the bottom panel.Clinical Interventions in Aging 2008:3(1) 134
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Action of BT on the motor unit
BT type A is a medication that has been used for nearly 
three decades to treat hyperactive muscle disorders, a 
variety of dystonias and movement disorders (Schantz and 
Johnson 1992). The mechanism for its action is that the 
toxin prevents release of membrane-bound ACh at the NMJ 
of striated muscle and causes a denervation and a paralysis 
of the muscle (Simpson 1992). The mechanism by which 
this occurs appears to result from toxin entering the nerve 
endings through endocytosis and inhibiting release of the 
vesicle-bound ACh within the nerve terminal itself. The BT is 
internalized into the neuron and then acts as a zinc-dependent 
endoprotease to disrupt some of the peptides required for 
release of the ACh. This action may take a couple of weeks 
to be completed. It destructs the NMJ resulting in muscular 
paralysis. It may take up to six months post injection, for the 
terminal axonal endings and the neuromuscular junctions to 
reconstitute themselves. Hambleton (1993) has noted that 
the toxin also enhances the ongoing turnover of NMJs, thus 
initiating physical recovery before full functional recovery. 
The changes in muscle following BT injection have been 
studied (Duchen 1970, 1972). It appears that muscle atro-
phy induces axonal sprouting. However, the regenerating 
axons appeared to branch in complex arrangements which 
were unable to establish functional connections for several 
weeks after injection. Once connections were established, the 
process of reconstituting denervated muscle proceeded in a 
normal fashion. Pestronk and Drachman (1978) demonstrated 
that the amount of sprouting was correlated with the number 
of ACh receptors which in turn played an important role in 
inducing sprouting in denervated muscle.
De Paiva et al (1999) studied the functional repair of 
motor end plates following BT injection. They found that 
the initial axonal sprouts were responsible for nerve-muscle 
transmission. A distinct second phase in the restoration 
process was found. It consisted in turning over of function 
Figure 2 Spectrograms of the phrase “When the sunlight …” spoken by a 74 year old female: normal control subject is depicted on the top panel, ADSD before BT injec-
tion is on the middle, and ADSD after BT injection is on the bottom panel.Clinical Interventions in Aging 2008:3(1) 135
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to the original terminals, causing the now superﬂ  uous (ini-
tial) sprouts to withdraw. The authors conclude that these 
initial sproutings are “functionally” essential to the repair 
process in paralyzed muscles. These ﬁ  ndings support earlier 
work by Duxson and Vrbová (1985), who showed that the 
rate at which superﬂ  uous sproutings (initial nerve termi-
nals) retract from the developing NMJ is regulated by the 
frequency of activation of the muscle. Thus, de Paiva et al 
(1999) conclude that axonal growth occurring as a second-
ary effect of BT injection, does not permanently establish 
new NMJs. Rather, the initial axonal sprouting serves as 
a mechanism to initially activate paralyzed muscle ﬁ  bers 
in the early weeks-to-months post-injection. As the parent 
end plate/muscle ﬁ  bers become more active, the initial 
sproutings, now superﬂ  uous, become withdrawn. Of note 
is the interaction between age and BT effect, relative to 
duration of motor end plate response. Both Knutsson et al 
(1969) and Davidson and Ludlow (1996) found that the 
duration of motor end plate response and its variability were 
signiﬁ  cantly, positively correlated with age. Davidson and 
Ludlow (1996) attributed the increased duration of motor 
unit response to the inefﬁ  ciency of collateral sprouting 
which they noted begins to decrease in one year. Thus, the 
reﬁ  nement of motor unit activity may last for years after 
injection (3 years in subjects in their study).
Normal vocal aging
The role of the vocal folds in vocal aging
In the current paper, the balance of this literature review will 
focus on the vocal folds, because of their central importance 
to mechanics of ADSD and its treatment with BT.
Structures in the larynx undergo a variety of age-
related changes. The heterogeneity of affected structures 
is illustrated in Figure 3. It shows a complex organization 
of tissues which are the underpinnings for such diverse 
functions as protection of epithelial surfaces through 
lubrication and immunologic beneﬁ  ts of laryngeal glands, 
imbuing viscoelastic and biomechanical properties to 
cartilages and the vocal folds and enabling them to 
respond to various mechanical stressors to which they are 
exposed, as well as providing a skeletal support for the 
laryngeal cavity and other soft tissues. The neuromuscular 
tissues are involved in important protective reﬂ  exes and 
regulatory mechanisms of the airways. Voice production 
is the byproduct of many of these intrinsic properties of 
the larynx, but especially the vocal folds whose unique 
responses to aerodynamic forces create the source of energy 
for speech production.
Epithelium and lamina propria of the vocal 
folds
Morphologic changes in the vocal folds of aged speakers involve 
changes in the epithelium, lamina propria, and neuro-muscular 
tissues. These changes neither occur uniformly, nor to the same 
extent in men and women. Given the layered structure of a vocal 
fold, changes in it must be viewed from the superﬁ  cial surface 
inwardly. The surface epithelium becomes thinner and altered in 
surface architecture with aging (Noell 1962). These surfaces are 
less robust and made more vulnerable by the effects of atrophy 
of mucous glands. The glands reduce the quantity and quality of 
their secretion (Gracco and Kahane 1989; Sato and Hirano 1998) 
which changes the normal rheologic properties of the surface, 
reduces protection against contact pressures and aerodynamic 
shearing forces, and compromises mucocilliary transport and 
immunologic competency. Distinctive characteristics of involu-
tion to the mucosa and submucosal connective tissues (lamina 
propria) have also been noted. This observation is important, 
because the layers of the lamina propria contribute in distinctive 
ways to the mobility of the vibrating surface of the vocal fold 
and to the longitudinal stability of it during vibration (Gray et al 
1999). Several changes in the lamina propria occurred with aging 
had been studied extensively. These involutional changes include 
alteration in the structure and organization of the elastic and 
collagenous ﬁ  bers ( Kahane 1987; Sato and Hirano 1997; Hirano 
et al 2000; Sato et al 2002; Madruga de Melo et al 2003), reduc-
tion in the ability to synthesize these ﬁ  brous proteins (Sato et al 
2004), alterations in composition and decrease in quantity of 
ground substance (Thibeault et al 2002). Figure  4 is an illustra-
tion of these types of changes, providing cross sections of adult 
vocal folds at various ages. The effects of altering the physical 
properties of the lamina propria include reduction of the tensile 
strength of the scaffolding of the vocal folds, alteration of its 
viscoelastic properties (ie, making it stiffer) and in the shape of 
the vibrating edges of the vocal folds. These changes, reduce 
stability of the vocal folds during vibration and adversely affect 
vocal efﬁ  ciency, contributing to voice quality deviations (Honjo 
and Isshiki 1980; Linville 1996).
Intrinsic laryngeal muscles
Changes in intrinsic laryngeal muscles have been found in aging 
larynges (Ferreri 1959; Hommerich 1972; Sato and Tauchi 
1982; Rodeno et al 1993) and have been attributed to reduction 
in muscle force and efﬁ  ciency. These aging muscle changes 
may occur more generally in the animal kingdom, as evidenced 
by Mardini (1987), who found that in an aging baboon, the TA 
muscle contracted more slowly, fatigued more readily, and 
took longer to recover than in younger animals. In rats and Clinical Interventions in Aging 2008:3(1) 136
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humans, who have been studied most extensively, TA muscle 
changes have been postulated to result from arteriosclerotic 
changes in the vessels (Ferreri 1959; Hommerich 1972) or 
from disturbance in sympathetic innervations (Bach et al 1942). 
Disagreement exists as to whether aging changes affect both 
sexes equally and all muscles uniformly (Carnevalle-Ricci 
1937; Ferreri 1959). Some authors maintain that there is a 
predilection for the adductor muscles (Bach et al 1942) to be 
more affected than the abductors (Malmgren and Gacek 1981). 
Suzuki et al (2002) reported that in rat laryngeal muscles, aging 
had greatest affect on adductory function by altering ﬁ  ber 
type composition to an isoform of myosin, which is slower 
contracting and similar to what occurs in denervation. The 
TA muscle – the principal muscle of the vocal fold – has been 
studied extensively in the last two decades. Its involution has 
been attributed to atrophy which has been causally linked to 
Figure 3 Coronal section of the larynx from 56 year old female illustrating major structural landmarks. Safran-Hematoxylin Stain, 2.5x original magniﬁ  cation. 1 – epiglottis, 
2 – unossiﬁ  ed thyroid cartilage, 3 – ossiﬁ  ed portion of thyroid cartilage, 4 – unossiﬁ  ed cricoid cartilage, 5 – ossiﬁ  ed portion of cricoid cartilage, 6 – lamina propria of vocal 
fold, 7 – thyroarytenoid muscle (the major constrictor of vocal fold), 8 – laryngeal ventricle (lined of glandular epithelium), 9 – vestibular fold with G – mucous-serous glands, 
10 – conus elasticus, 11 – glottal space.Clinical Interventions in Aging 2008:3(1) 137
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Figure 4 Coronal sections of the vocal fold from 21years old (A), 63 years old (B) and 72years old (C) females illustrating age related changes in the epithelium and lamina 
propria. Safran-Hematoxylin Stain, 20x original magniﬁ  cation. E – epithelium, S – superﬁ  cial layer of the lamina propria, I – intermediate layer of the lamina propria, D – deep 
laryner of the lamina propria. Portions of the adjacent thyroarytenoid muscle (TA), which form a part of the body of the vocal fold, are also illustrated.Clinical Interventions in Aging 2008:3(1) 138
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altered metabolic processes (Kersing and Jennekens 2004), 
aging contractile proteins (Mardini et al 1987), alteration in ﬁ  ber 
type composition (Rodeno et al 1993; Malmgren et al 1999; 
Suzuki et al 2002) and degenerative changes caused by subtle 
amounts of denervation and poor or inefﬁ  cient reconstitution 
of NMJs (Prakash and Sieck 1998). Sato and Tauchi (1982) 
found that aging appeared to have a differential effect on ﬁ  ber 
types within the TA muscle. Slow fatigue resistant (type I) 
ﬁ  bers were found to degenerate rapidly than fast fatigue prone 
(type II) ﬁ  bers after age 60. Type II ﬁ  bers declined more rapidly 
after age 70 and both types signiﬁ  cantly declined after age 80. 
The functional consequences during voice production of these 
muscle changes relate to (a) inaccurate positioning of the vocal 
folds for various voicing gestures, (b) reduced adductory forces 
needed to approximate the vocal folds during voice production 
and (c) altered or deﬁ  cient muscular-mechanics needed to 
transiently change the physical properties of the vocal folds for 
rapid adjustments for modulation of pitch during speech.
Incomplete glottic closure
Incomplete closure of the glottis (space between the vocal 
folds) is one of the characteristic deﬁ  cits in vocal mechanics 
observed in the aging speaker (Tanaka et al 1994). This 
condition referred to as bowing of the vocal folds is thought to 
result from atrophy of the lamina propria and thyroarytenoid 
muscle. This condition is illustrated video-stroboscopically 
in Figure 5. The lack of complete closure of the glottal chink 
by the adducted vocal folds may alter voice in several ways: 
(a) by reducing subglottal pressure required to maintain vocal 
fold oscillation and allow for adequate loudness; (b) allowing 
for the introduction of a competing noise to the vocal fold 
signal. This results from unmodulated airﬂ  ow (noise) passing 
between the vibrating folds, whose vibration may also be 
disturbed (frequency and amplitude perturbations), because 
of changes in its mechanical properties. Disruption in the 
positioning of the vocal folds and in timely response to 
muscular forces may possibly be inﬂ  uenced by changes in the 
cricoarytenoid joint (Kahn and Kahane 1986; Kahane 1988). 
Alterations in articular surfaces, synovial tissues and joint 
capsule may inﬂ  uence the speed and accuracy with which 
vocal folds can be positioned during voicing.
Changes in innervation
Altered innervation within the aging larynx and to the vocal 
folds (TA muscle) involves changes to both the peripheral 
nerves and NMJs. Kawabuchi and colleagues (2001) provide 
insight into normal aging alterations in NMJs from their 
study of reinnervation of the crushed sciatic nerve in 64 rats 
(30 adult and 34 aged). They have found that the processes 
involved in reinnervation were dramatically altered in aged 
rats compared to younger adult counterparts. Salient differ-
ences included alterations in their morphology of Schwann 
cells in aged nerves, and in their arrival at developing ACh 
receptor sites. The diminished inﬂ  uence of the Schwann 
cells alter the architecture of the ACh receptor sites. The 
outgrowth of terminal Schwann cells in aged nerves appeared 
Figure 5 Endoscopic pictures of the vocal folds of a 58 year old woman during phonation, who presents with bowing of the vocal folds, thinning lamina propria and a 
persistent glottal chink.Clinical Interventions in Aging 2008:3(1) 139
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to adversely affect regenerating axons in their ability to 
interconnect with motor endplates. The authors suggested 
that reduction in trophic support for neurons may result in 
greater muscle atrophy following denervation.
Both superior (SLN) and recurrent laryngeal nerves 
(RLN) have been shown to undergo some degenerative 
changes with increasing age in studies where rat (Malmgren 
and Ringwood 1988) and human nerves (Gambino et al 1990; 
Mortelliti et al 1990; Périé et al 1997; Nagai et al 2005) were 
used. Decreased numbers of ﬁ  bers have been demonstrated 
in SLN (Mortelliti et al 1990) and RLN (Malmgren and 
Ringwood 1988). Distal axonal degeneration to the intrinsic 
laryngeal muscles was reported by Périé et al (1997). Another 
study (Gambino et al 1990) brings evidence to suggest that 
the posterior cricoarytenoid (PCA) muscle may be more 
robust than other intrinsic muscles, in that NMJs showed 
no signiﬁ  cant age related changes. This may, in part, be 
explained by the important functional role played by the 
PCA, as the sole muscle responsible to ensuring patency of 
the airway. The effects of deﬁ  ciencies in laryngeal sensory 
innervation to motor control and muscle integrity have been 
discussed by Nagai et al (2005). In their study of selectively 
denervated rats, they found that deficits in laryngeal 
sensation altered the myosin heavy chain composition, which 
signiﬁ  cantly inﬂ  uences muscle contraction time. Myosin 
heavy chain replacement or transformation to slower isoforms 
have been shown to be caused by aging and injury to the RLN 
(DelGaudio and Sciote 1997; Suzuki et al 2002).
The NMJ in aging laryngeal muscles appear to undergo 
structural changes which result in altered functioning of 
the vocal folds. These changes, drawn from studies of rat 
larynges, clearly indicate that the altered NMJ and motor end 
plate are related to degeneration of the RLN and attempts 
to reinnervate the TA muscle. Malmgren and Ringwood 
(1988) and Malmgren et al (1999) reported that there was a 
loss in motor units in the aging TA muscle, resulting from 
degeneration in the RLN. Further, the reconstituted NMJ 
were structurally deﬁ  cient, having signiﬁ  cantly reduced ACh 
receptor sites, variability in the architecture of the end plate 
(Connor et al 2002), and abnormalities in the pre-terminal and 
terminal regions as well as poor terminal axon morphology 
(Kawabuchi et al 2001). In the TA, large motor units were 
affected more than the smaller ones. The aging changes 
have been likened to those which characterize reinnervation; 
however they are less precise and functionally produce greater 
duration of response. This was not observed in human subjects 
younger than 60 year old (Takeda et al 2000). An additional 
issue worth considering in an older patient with ADSD is 
the relationship of reconstitution of the NMJ following BT 
injection with the previously noted effects of aging.
Despite the primary importance of the larynx in voice 
production, it would be erroneous to view it as the sole 
contributor to the characteristics of the aging voice. As shown 
in Figure 6, the peripheral speech mechanism is composed 
of many structures of the upper aero-digestive system, 
which are integrated into a highly coordinated apparatus 
designed to modulate air pressure and air flow. From a 
mechanical viewpoint, it consists of a series of valves and 
passageways whose geometry is transiently changed as it 
conditions air pressure and air ﬂ  ow into distinct and familiar 
outputs recognized as articulated speech and voice. Intrinsic 
changes within the larynx attributed to aging, may impact 
on vocal functioning by altering pitch, reducing loudness, 
introducing noise into the source (tonal) signal and altering 
voice quality.
Clearly, laryngeal aging adversely affects voice production 
by altering the integrity of the vocal folds resulting in reduced 
mechanical and metabolic capacities which affect efﬁ  ciency 
and economy of function, as well as restorative capabilities. 
Ramig and Ringel (1983) have shown that physiological 
rather than chronological aging appears to have the greatest 
impact on the integrity of speech and vocal functioning. Not 
all organs or systems age concurrently and to the same extent. 
Nor are all of the typical perceptual characteristics assigned 
to an “older sounding voice” related to natural involution of 
the vocal folds (Woo et al 1992). Extralaryngeal factors may 
Figure 6 Diagrammatic representation of the major structures contributing to the 
peripheral speech mechanism. Structures of the upper and lower respiratory tracts are 
functionally interfaced and programmed by the CNS to produce voice and speech.Clinical Interventions in Aging 2008:3(1) 140
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also contribute to altered vocal functioning in the elderly 
and include the effects of medication, which may cause 
deﬁ  ciencies in hydration and proprioception and by such 
systemic conditions as gastroesophageal reﬂ  ux. Additionally, 
research data have shown that there are many changes in 
supralaryngeal cavities and structures, which contribute to 
the altered efﬁ  ciency and perception of aging in the voice. 
A brief summary of these effects follows.
Supralaryngeal contributions to aging voice
In addition to the laryngeal contributions to aging of the 
voice, numerous reports have been published illustrating 
the changes within the supralaryngeal speech mechanism 
may affect the quality of speech production (Kahane 1981, 
1990; Linville 1996). Examples include reduced precision 
of articulation (Hartman 1979; Amerman and Parnell 1990), 
difﬁ  culties in maintaining ﬂ  uency under circumstances of 
high cognitive stress (Duchin and Mysak 1987), reduced 
rate of speech (Benjamin 1982; Liss et al 1990), reduction 
in phoneme duration for consonants and vowels (Forrest 
et al 1989; Morris and Brown 1987, 1994), use of greater 
intonation and contrastive stress (Scukanec et al 1996), 
perhaps as compensatory measures for speech changes 
noted, and formant frequency alterations. Formant frequency 
alterations for vowels are a measure of vocal tract resonance 
and stability. Though velopharyngeal function has not been 
shown to change signiﬁ  cantly with aging (Hoit et al 1994), 
vocal tract efﬁ  ciency may become decreased as resonatory 
capabilities are changed by hypotonicity of pharyngeal 
musculature, lengthening of the vocal tract, through a com-
bination of lowering of the larynx and changes in intraoral 
morphology (Endres et al 1971; Xue and Hao 2003), and a 
tendency for speakers to adopt more restricted articulatory 
posturing (centralization) during vowel production.
Some normal, age related speech alterations are evident 
in Figure 2 (top panel), wherein the older speaker exhibits 
weak intensity during production of “when” as well as slight 
prolongation of /s/ in “sun.” Vowels exhibit some stippling 
(aperiodic energy) in the higher frequencies, suggesting 
breathiness. Overall rate of syllable production is slightly 
slower in the older normal speaker compared to the younger 
normal speaker in Figure 1 (top panel).
Aging and ADSD
Untreated ADSD has not been observed to worsen with 
advancing age, suggesting that it is not a degenerative 
disorder (Aronson 1990). Brodnitz (1976) examined age of 
onset in 130 cases reporting an average age of 50 years, with 
onsets ranging from the 20s (10 per cent) to 60 and older 
(18 per cent). The effect of aging upon treatment outcome 
in ADSD has not been well studied. Two of the primary 
efﬁ  cacy studies, for example, did not report age data for 
their ADSD patient samples (Truong et al 1991; Blitzer 
et al 1998). BT treatment studies have reported a broad age 
range of ADSD. For example, Whurr et al (1993) report 
subjects’ ages ranging from 31 to 82 years with a mean of 
57 years (N = 31), while Langveldt et al (2001) reported an 
age range of 32–72 years with a mean of 47 (N = 46). Neither 
of these studies, however, examined aging as a treatment 
outcome factor.
To date four studies have examined aging with respect 
to response to BT injection in ADSD. Ford et al (1992) ﬁ  rst 
examined the correlation between age and initial BT treatment 
outcome and found it to be statistically non-signiﬁ  cant. 
This may have been due to the fact that their subject pool 
consisted of patients with both ADSD and ABSD. ABSD 
did not respond favorably to BT injection of the vocal folds, 
in contrast to the signiﬁ  cant beneﬁ  t observed for those with 
ADSD. Computing a correlation of treatment outcome with 
age for all subjects combined, but not partitioning by disorder 
type, may have suppressed age related variance in treatment 
outcome for ADSD. Another factor that may have diminished 
the correlation was overall pre-treatment severity. Ford et al 
(1992) reported that overall severity strongly inﬂ  uenced 
treatment outcome, but it was not controlled in their analysis 
of aging. Subsequently, Lundy et al (1998) examined patient 
self-ratings of outcome following initial BT injection. They 
found that older patients rated their outcomes more poorly 
than younger patients. They also found, however, that greater 
levels of pre-injection severity of dysphonia and the presence 
of movement disorders elsewhere in the body also were more 
prevalent in the older subjects. Because these variables were, 
in themselves strong outcome predictors, the effect of aging 
on response to BT, while signiﬁ  cant, was felt to be somewhat 
confounded with overall severity of the disorder. Wingate 
et al (2005), examined pre-to-post BT injection change in a 
group of 13 older patients with ADSD, ranging in age from 65 
to 77 years, who had been receiving BT injections for at least 
one year. Their results, based on a patient self-rating index of 
functional outcomes, demonstrated no statistically signiﬁ  cant 
change from pre-to-post injection. Several patients, however, 
reported that their voices did improve.
Cannito et al (2004) directly examined the quality of 
speech produced by older and younger persons with ADSD 
using perceptual scaling judgments in a single-blind pre-
post treatment design. Speakers with ADSD ranged in age Clinical Interventions in Aging 2008:3(1) 141
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from 22 to 79 years with a mean of 53 years. The patients 
were evaluated before and after their initial injection of BT 
into the vocal folds, during a period from approximately 
2.5 to 7.0 weeks post-injection. This time window was 
established by triangulating physiological and patient 
self-rating data obtained from three independent studies 
(Aronson et al 1993; Liu et al 1996; Fisher et al 1999) of 
the ﬁ  ne grained ﬂ  uctuations in post-injection vocal function. 
These studies have demonstrated that glottal competence 
begins to recover by approximately 2 weeks (Fisher et al 
1999), while vocal spasms attain maximal decrease by 
2 weeks and maintain that level for an additional 42 days, 
on average (Liu et al 1996). As a group the patients exhib-
ited a beneﬁ  cial response to BT injection, however, there 
were signiﬁ  cant variations as a function of pre-treatment 
severity of ADSD. The relationship of aging to magnitude 
of pre-to-post treatment change was also examined, with 
severity statistically controlled. Multiple regression analysis 
demonstrated that age accounted for a small but statistically 
signiﬁ  cant proportion of the variance in clinical change, 
such that the older the individual, the smaller the post-
injection improvement. It was also noted that of the nine 
subjects whose voices became worse following treatment, 
ﬁ  ve were older than 70 years.
Retrospective analysis
To more fully appreciate the inﬂ  uence of aging on response 
to initial BT injection, a reanalysis of the (Cannito et al 2004) 
data was undertaken to examine the response of ADSD to 
initial BT injection for each of ﬁ  ve age groups, and to com-
pare them with age matched normal controls.
Method
Forty-two subjects with ADSD were administered BT 
using the transcutaneous injection procedure under EMG 
guidance that was previously discussed. Their demographic 
and clinical characteristics are presented in Table 1. ADSD 
speakers were grouped according to chronologic age at 
the pre-treatment recording. For statistical analysis, two 
subjects in their 20s were pooled with seven subjects in 
their 30s to comprise the youngest age group. There were 
8 subjects in their 40s, 9 subjects in their 50s, 9 subjects in 
their 60s, and 7 subjects in their 70s. ADSD participants 
did not exhibit movement disorders elsewhere in the body, 
and did not have perceptible voice tremor. The age groups 
did not differ signiﬁ  cantly on the basis of injection side 
(ie, left, right, or both vocal folds), years post-onset of 
ADSD, dosage, or days post injection for second recording. 
Age and gender-matched non-dysphonic controls were 
similarly grouped by age.
Six listeners with expertise in voice disorders and six 
with expertise in ﬂ  uency disorders heard recordings of a 
standard oral reading passage obtained prior to BT injec-
tion and 3–6 weeks after injection from each of 42 speak-
ers with ADSD, and from 42 normal controls. Recordings 
were presented in a fully randomized order to each listener 
at conversational loudness levels in a psycho-acoustically 
controlled environment. They responded by positioning a 
mouse driven cursor on a colored histogram, displayed on a 
computer monitor, with end points labeled very good/very 
poor for each of four attributes of voice or ﬂ  uency depend-
ing upon the listener’s area of expertise. Table 2 provides 
deﬁ  nitions of the voice and ﬂ  uency attributes. Following 
preliminary training which gave them a common frame of 
reference with respect to the range of vocal behaviors to 
be scaled, listeners were instructed to judge each recording 
in terms of its deviation from their own internal standard 
of normalcy. Listeners were blinded as to speech sample 
conditions. The method yielded high levels of intra- and 
inter-listener reliability (See Cannito et al (2004). The mean 
of six judges visual analog scaling (VAS) scores for the four 
voice attributes and the mean of six judges VAS scores for 
the four ﬂ  uency attributes were computed for each speaker 
in each condition (ADSD pre-BT, ADSD post-BT, and 
Control). These served as observational units for statistical 
analysis.
Results
Figure 7 provides age-group plots of the mean VAS 
scores for the individual dependent variables for voice 
quality (overall voice quality, roughness, brokenness, 
breathiness) and Figure 8 provides mean VAS scores for 
individual variables for ﬂ  uency (overall ﬂ  uency, tension 
struggle, vocal spasms, dysﬂ  uent syllables). Inspection of 
these ﬁ  gures indicates some variation for speciﬁ  c variables. 
All of the ﬂ  uency variables as well as overall voice quality 
and roughness demonstrated a consistent pattern. The 70 
year old group showed little or no improvement after BT 
injection, but substantial improvement was noted for the 
other age groups. Brokenness appears to have improved for 
all age groups; however the smallest change was evident 
in the 70 year old group. Breathiness showed little change 
in the 40 and 50 year old groups, but became worse in the 
20, 60 and 70 year old groups, with the oldest speakers 
exhibiting the greatest amount of perceived post-treatment 
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VAS data were submitted to a mixed-effects repeated 
measure, multivariate analysis of covariance (MANCOVA). 
Age group was the between subjects variable, and speaking 
condition (pre-BT ADSD, post-BT ADSD, Control) was 
the within subject variable or repeated measure. There were 
four dependent variables for voice (overall voice quality, 
roughness, breathiness, brokenness) and four dependent 
variables for ﬂ  uency (overall ﬂ  uency, tension struggle, 
vocal spasms, and disﬂ  uent syllables). Pre-BT severity of 
ADSD served as the covariate in order to remove variance 
attributable to this known confounding variable, which 
was not uniformly distributed across the age range. Sex 
was treated as blocking variable in order to partition its 
variance, due to the small number of male subjects (n = 6) 
in the data set.
MANCOVA results demonstrated that there was a 
statistically signiﬁ  cant main effect of age group (p =  0.019), 
as well as a signiﬁ  cant interaction of speaking condition by 
Table 1 Characteristics of speakers with adductor spasmodic dysphonia
Age Gender  Initial  Years  Injection  Dosage  Days  post
years   severity SD  type  units  injection
22 F  Moderate  5  Unilateral  2.5  31
28 F  Mild  3  Unilateral  2.5  36
31 F  Mild  2  Unilateral  5  31
31 F  Severe  4  Unilateral  15  45
32 F  Mild  2  Bilateral  5  32
33 F  Moderate  4  Unilateral  2.5  50
38 F  Severe  9  Unilateral  15  38
38 F  Mild  5  Unilateral  2.5  23
38 F  Profound  4  Bilateral  2.5  22
41 F  Profound  16 Bilateral  2.5  34
41 F  Mild  4  Bilateral  10  44
42 F  Mild  4  Unilateral  2.5  27
42 M  Moderate  9  Unilateral  7.5  22
44 F  Mild  7  Unilateral  2.5  22
45 F  Severe  12 Unilateral  15  45
46 F  Moderate  9  Unilateral  15  34
46 F  Severe  9  Bilateral  2.5  43
51 M  Severe  4  Unilateral  30  29
51 F  Severe  1  Unilateral  5  36
52 F  Mild  19 Bilateral  1.5  34
52 F  Moderate  24 Unilateral  5  35
54 F  Profound  4  Bilateral  2.5  30
54 M  Moderate  9  Unilateral  7.5  27
56 F  Profound  16 Unilateral  30  34
56 F  Moderate  13 Unilateral  15  31
57 F  Profound  14 Bilateral  2.5  38
60 F  Severe  6  Unilateral  15  37
61 F  Profound  9  Bilateral  5  31
63 F  Moderate  11 Unilateral  15  31
63 F  Severe  9  Bilateral  5  17
64 F  Profound  10 Unilateral  15  29
64 F  Profound  11 Bilateral  2.5  27
64 F  Mild  10 Unilateral  1.25  27
67 F  Profound  13 Bilateral  2.5  51
67 M  Moderate  8  Bilateral  5  20
70 F  Severe  5  Unilateral  5  48
71 F  Mild  20 Unilateral  7.5  29
71 M  Severe  19 Bilateral  5  36
72 F  Severe  8  Unilateral  7.5  42
74 F  Severe  9  Bilateral  2.5  36
77 F  Severe  8  Unilateral  5  27
79 M  Mild  5  Unilateral  5  36Clinical Interventions in Aging 2008:3(1) 143
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age group (p = 0.006) with pre-treatment severity controlled. 
Given the absence of significant interactions involving 
individual variables, and in the interest of simpliﬁ  cation, 
voice and ﬂ  uency composite scores were computed. Means 
and standard deviations are provided by age group for each 
perceptual composite score based on the voice and ﬂ  uency 
attributes in Table 3. These represent aggregates of the four 
rated attributes of voice and of ﬂ  uency, and reﬂ  ect mean 
listener judgments of the overall goodness of the speakers’ 
voice and ﬂ  uency.
Figures 9 and 10 depict the signiﬁ  cant age by treatment 
interaction effect for voice (Figure 9) and for fluency 
(Figure 10). Post hoc means comparisons demonstrated that 
there were statistically signiﬁ  cant differences (p  0.05) 
between all ADSD age groups and their age-matched control 
samples before and after BT injection. All ADSD age groups 
demonstrated statistically signiﬁ  cant improvement from pre-
to-post BT injection (p  0.05), with the exception of the 
70–79-year-old group, who exhibited little change following 
treatment. A precipitous decline in post treatment mean 
scores exhibited by the oldest ADSD group also is evident 
in Figures 9 and 10. In addition, the 70–79-year-old normal 
controls differed signiﬁ  cantly from the other control subject 
age groups, who did not differ from each other. Figures 9 
and 10 also demonstrate the decline in voice quality and 
ﬂ  uency exhibited by the oldest control age group. While some 
attenuation of voice quality was evident in the 60–69 year old 
group, it did not attain statistical signiﬁ  cance (p = 0.13).
Table 2 Attributes of voice and ﬂ  uency for perceptual scaling experiments
Attribute Description  End  points
Voice scaling experiment 
Overall voice quality  A general perceptual impression of an   Extremely good/ 
  appropriate degree of melodiousness   Extremely poor
  periodicity, and richness of the tonal  
  components of the voice exhibited across  
  the speech sample 
Breathiness  Audible occurrence of breath noise or   Absent/Pervasive
  acoustic turbulence in the voice signal  
  perceived either as “whispery” or  
  “murmured” quality across the speech  
 sample 
Roughness  Audible occurrence of acoustic aperiodicity   Absent/Pervasive
  in the voice signal perceived as either  
  “harsh,” “gruff” or “strained-strangled”  
  quality across the speech sample.  
Brokenness  Audible occurrence of the unexpected   Absent/Pervasive
  momentary absence of the voicing signal  
  perceived as “gaps” or “cracks” in voicing  
  across the speech sample 
Fluency scaling experiment 
Overall ﬂ  uency  A general perceptual impression of the   Extremely good/ 
  prompt, smooth, easy and continuous   Extremely poor
 forward  ﬂ  ow of speech exhibited across the  
 sample. 
Tension struggle  Perceived occurrence of audible effort,   Absent/Pervasive
  hesitation and straining to initiate or  
  maintain the forward ﬂ  ow of speech across  
 the  sample. 
Disﬂ  uent syllables  Perceived occurrence of inappropriate   Absent/Pervasive
  syllables that are repeated, added, or  
  prolonged within the ongoing ﬂ  ow of  
  speech across the sample. 
Vocal spasms   Perceived occurrence of quavering,   Absent/Pervasive
  squeezing or stoppage of the voice  
 sufﬁ  cient to disrupt the ongoing ﬂ  ow of  
  speech across the sample 
Reprinted with permission from Cannito MP,   Woodson GE, Murry T, et al. 2004. Perceptual analyses of spasmodic dysphonia before and after treatment. Arch Otolaryngol 
Head Neck Surg, 130:1393–9. Copyright © (2004),  American Medical Association.   All rights reserved.Clinical Interventions in Aging 2008:3(1) 144
Cannito et al
A number of potentially confounding variables were 
free to vary in the present study, due to the retrospective 
nature of the sample, which one might argue could account 
for apparent age-related ﬁ  ndings. Speciﬁ  cally, dosage units 
for BT administration, site of injection (ie, unilateral vs. 
bilateral TA muscles), and number of days post injection 
until audio recording. It is possible that age-biased distribu-
tion of these variables may have introduced variability that 
contributed to the observed results, if in fact these variables 
could be shown to have a signiﬁ  cant impact on the pres-
ent speakers response to BT. Analyses were conducted to 
examine the inﬂ  uence of these potential confounds in the 
present data set. Table 4 provides mean values for these 
variables by age group.
Dosage levels for the oldest group were in the midrange 
of total units (2.5–7.5 units) and were comparable to that of 
the youngest group. The single lowest dosage of 1.25 units 
occurred in the 60 year olds, while the 50 year olds included 
two cases who received the highest dosages of 30 units. Yet 
both of these groups showed substantial beneﬁ  t. Age group 
means for days post injection varied from 30 (for 60 year 
olds) to 36.29 (for 70 year olds). Univariate ANOVAs for 
dosage and days post injection did not differ signiﬁ  cantly 
across the age groups (p  0.10). Site of injection varied 
from 7 unilateral injections in the 30 year olds, to 4 unilateral 
injections in the 60 year olds, whereas the 30 year old and 
70 year old group each included two bilateral injections. 
Chi-square analysis demonstrated no signiﬁ  cant difference 
(p = 0.654) in the distribution of unilateral versus bilateral 
injection on the basis of age group. Taken individually, there 
were no signiﬁ  cant correlations (p  0.10) of these variables 
with age or with response to BT (deﬁ  ned as the pre-to-post 
injection difference score). Multiple regression analysis also 
demonstrated that a linear combination of these variables was 
not signiﬁ  cantly predictive of response to BT (p  0.10), 
nor was it predictive of age (p  0.10).
Figure 7 Age-group plots of the means and standard deviations of visual analog scaling (VAS) scores for the four voice attributes (overall voice quality, roughness, brokenness, 
breathiness).
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Conclusions
The present analysis demonstrates a number of interesting 
ﬁ  ndings. First, the oldest controls, while still performing 
within a relatively normal range of perceived voice quality 
(ie, signiﬁ  cantly better than the disordered groups), were 
perceived to have poorer voice and ﬂ  uency than their younger 
counterparts. This is consistent with expectations regarding 
aging of the larynx and speech mechanism. Second, untreated 
ADSD was not perceived to deteriorate as a function of age. 
There were no signiﬁ  cant differences between younger and 
older age groups prior to treatment. This is consistent with 
prior studies (Aronson et al 1993; Brodnitz 1976). Third, fol-
lowing treatment there was a substantial improvement for all 
age groups with ADSD except the 70–79 year olds. As it is 
evident in Figures 9 and 10, the distribution of ADSD mean 
scores, even after treatment, occurs in a distinctly different 
range of perceived vocal/ﬂ  uency function than that of normal 
controls. It is therefore likely that the perceptual salience of 
ADSD overrides and obscures the more subtle effects of nor-
mal vocal aging, such as that exhibited by the older controls. 
Following treatment, aging voice alone could have accounted 
for only a small percentage of the perceived severity of 
the oldest ADSD group. It remains possible, however, that 
sensitive physiological studies (eg, air ﬂ  ow and air pressure 
measures) may be able to demonstrate some age related 
differences in untreated ADSD. Third, the oldest ADSD 
subjects studied (70–79-year-olds) did not exhibit expected 
improvement in response to BT injection of the vocal folds. 
This was not a gradual shift in response over the age range, 
but rather an abrupt change demonstrated only in the oldest 
group. The facts that they did not demonstrate merely an 
attenuation of improvement following treatment, in com-
parison with the other age groups, and that several of these 
older speakers actually worsened after BT injection, strongly 
suggest that there may indeed be a physiological interaction 
between aging laryngeal tissues and BT injection.
Figure 8 Age-group plots of the means and standard deviations of visual analog scaling (VAS) scores for the four ﬂ  uency attributes (overall ﬂ  uency, tension struggle, vocal 
spasms, dysﬂ  uent syllables).
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General discussion
Botox therapy is the method of choice for treating ADSD. 
The effects of aging on BT treatment effectiveness are not 
well understood or documented. Ford et al (1992) have 
suggested that age does not inﬂ  uence the effectiveness of 
BT treatment of ADSD. This is a striking ﬁ  nding, given 
the results of others who showed that physiological aging 
and health status (Ramig and Ringel 1983) and systemic 
conditions affecting the aged, such as atherosclerosis 
(Orlikoff 1990), contributed signiﬁ  cantly to vocal instability 
and depreciated voice quality, when analyzed with regard 
to the performance of all younger cohorts studied. In both 
studies, the authors reported that poorer voice production 
was observed in the oldest age groups (subjects older than 
age 60). This corresponds well with the oldest group in our 
study. It also appears to support the notion that there is a 
critical period when the aggregate of the involutional changes 
begin to be reﬂ  ected in perceived differences in normal vocal 
functioning (Kahane 1990; Linville 1996).
Evidence from the current study showed that voices 
of older normal subjects differed signiﬁ  cantly from older 
ADSD counterparts. This underscored the fact that vocal 
instability and alteration in speech ﬂ  ow in normal aging is 
different from that observed in older ADSD subjects. Not 
only were the oldest ADSD voices quantitatively different 
from all other subjects post injection, they were perceived as 
having the poorest voice quality of all the ADSD subjects. 
These ﬁ  ndings suggest that in both normal and ADSD aged 
speakers, age related intrinsic changes in the vocal folds and 
vocal tract alter the physiological capabilities of the phonatory 
mechanism. However, the ADSD subjects have the addition 
of a focal dystonia superimposed upon normal involutional 
changes within the larynx. It thus appears that BT injection 
is not able to reconstitute the vocal mechanism of these older 
ADSD voices to expected levels of functioning, though 
these are inherently mechanically less efﬁ  cient than younger 
mechanisms. In the present study, however, these normal 
aging changes were not sufﬁ  cient to account for the depressed 
treatment outcomes of the older ADSD speakers.
Of particular relevance to the poorer quality of voice and 
ﬂ  uency of older speakers with ADSD after BT injection, is the 
possibility that the older vocal folds respond less effectively 
to BT therapy for several reasons. These include:
1.  Degenerative changes in the SLN and RLN (Malmgren 
and Ringwood 1988; Mortelliti et al 1990) and resulting 
regressive changes in the vocalis muscle of the vocal folds 
(DelGaudio and Sciote 1997; Périé et al 1997; Suzuki 
et al 2002).
2.  Loss of motor units in the TA muscles, resulting from 
degeneration in the recurrent laryngeal nerve fibers 
(Malmgren and Ringwood 1988; Mortelliti et al 1990). 
Functional decline in the vocal fold musculature in ADSD 
reported from EMG studies by (Davidson and Ludlow 
1996), may be reﬂ  ecting these changes.
Table 3 Means and standard deviations of composite scores for voice, ﬂ  uency, and overall scores are shown for three groups: 
controls,   ADSD subjects before and after BT injection by age group*
Decades Composite  voice  Composite  ﬂ  uency  Composite overall
 Mean  SD  Mean  SD Mean  SD
Non-dysphonic controls
30 97.51 1.67  98.57  1.72  98.04 1.61
40 96.65 2.47  99.06  0.54  97.85 1.34
50 96.90 1.19  98.36  0.91  97.63 0.73
60 96.43 1.83  97.03  2.54  96.73 2.10
70 93.59 3.72  96.08  2.72  94.84 2.62
Pre BT injection
30 57.31 24.99 58.18  26.80  57.74 25.72
40 55.99 23.05 57.26  27.06  56.62 24.93
50 40.09 18.85 40.71  20.68  40.40 19.61
60 44.61 13.29 42.81  22.74  43.71 17.92
70 48.88 20.46 48.99  24.0  48.93 22.05
Post BT injection
30 70.75 15.19 81.85  15.92  76.30 15.12
40 70.52 15.78 80.19  17.27  75.35 16.12
50 63.97 16.65 75.07  22.19  69.52 19.20
60 62.64 12.81 71.90  13.42  67.27 12.26
70 48.07 14.56 50.17  18.14  49.12 16.14
* Values adjusted for the covariates of severity and gender.Clinical Interventions in Aging 2008:3(1) 147
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3.  Structural abnormalities in ACh receptor site architecture 
as seen in the aging rat vocal folds (Connor et al 2002).
4.  TA muscle atrophy and associated connective tissue 
changes within the vocal folds, may alter the geometry 
of the muscle so as to compromise the location of the 
choice injection site – center of muscle – the region of 
highly concentrated motor endplates (Shaari et al 1991). 
Thus, despite the most exacting technique, the clinician 
may achieve a less than maximal result, due to the altered 
nature of the vocal fold musculature.
5.  Poorer localization of the Botox within the musculature 
of the vocal fold (unwanted spread from injection sites) 
because of hampered diffusion resulting from changes 
in the interstitial ground substance (Thibeault et al 2002) 
and altered architecture of connective tissues within the 
TA muscle (Kahane 1987; Shaari et al 1991). This view-
point is supported by concerns regarding injection of the 
orbicularis oculi, for blepharospasm, where ﬁ  brosis and 
atrophy have been noted in humans treated with repeated 
BT injection (Assessment: the clinical usefulness of 
botulinum toxin-A in treating neurologic disorders. 
Report of Therapeutics and Technology Assessment 
Subcommittee of the American Academy of Neurology 
1990).
Though normal aging appears to prompt several natural 
involutional changes in the vocal folds, changes in its 
neuromotor integrity may be the most signiﬁ  cant feature 
in destabilizing the vocal folds and voicing of individuals 
with ADSD. This situation appears to become further 
compromised by the effects of BT injection. The recovering 
voice of the aged speaker may beneﬁ  t form BT less than 
younger counterparts, because the very motor units, targeted 
Figure 9 Interaction plots of decade by treatment condition for mean composite 
scores for voice for three groups: non-dysphonic controls, ADSD before BT injec-
tion and the same ADSD subjects after BT injection.
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Figure 10 Interaction plots of decade by treatment condition for mean ﬂ  uency 
composite scores by decade for three groups: non-dysphonic controls, ADSD before 
BT injection and the same ADSD subjects after BT injection.
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Table 4 Treatment characteristics for ﬁ  ve age groups of ADSD
Decade  N  Mean dosage  Mean  Type of   Type of 
    (Total Units)  days post   injection  injection
      injection  No. Unilat  No. Bilat
30 year olds*  9  5.83  34.22  7  2
40 year olds  8  7.19  33.88  5  3
50 year olds  9  11.00  32.67  6  3
60 year olds  9  7.36  30.00  4  5
70 year olds  7  5.36  36.29  5  2
*Two 20-year-olds were included in this group for statistical analysis.Clinical Interventions in Aging 2008:3(1) 148
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in treatment, are biologically less robust and may be less 
able to regenerate (fully or normally) because of deﬁ  cient 
structural and atrophic properties. It may be prudent to temper 
expectations for signiﬁ  cantly improved voice in older ADSD 
speakers, because their vocal mechanism is inherently less 
capable of reconstituting itself.
In both normal and ADSD older voices, vocal changes 
result from such conditions as: (1) altered patterns of vocal 
fold vibration; (2) reduced responsiveness of the vocal 
folds to subglottic pressure because of their decreased 
viscoelastic properties; (3) reduction in vocal control 
mechanisms because of vocal fold muscle atrophy which 
affects the efﬁ  ciency of transiently changing the physical 
properties of the vocal folds (length, tension, mass/unit 
area), overcoming incomplete glottal closure (bowing); 
and (4) reduced efﬁ  ciency of transmission of the glottal 
(source) signal through the vocal tract because of decreased 
tonicity of the pharyngeal walls and reduced efﬁ  ciency of 
articulatory valving.
Depreciated voice quality in the older ADSD subjects 
after BT treatment also may have been influenced by 
frequently used medications, such as diuretics prescribed for 
such conditions as control of high blood pressure, cardiac, 
urologic or renal problems. These are, of course, often 
experienced by older people. Additionally, medications such 
as bronchodialators for temporizing symptoms of asthma or 
those related to interstitial lung disorders, may adversely 
affect voice quality by drying the vocal fold mucosa and 
reducing proprioceptive feedback. These variables were 
not monitored in the current study and remain a subject for 
further research.
Another contributing factor to poor voice quality in the 
older ADSD subjects may be increased anxiety and feelings 
of frailty and vulnerability, which have been heightened 
by their disabled communication and discomfort created 
by laryngeal spasms and respiratory compromise resulting 
from it. These feelings may become reinforced by the ini-
tially weak voice following BT injection, and the failure to 
attain normal voice production after treatment. Psychosocial 
responses in older ADSD subjects should be examined in 
future studies.
It should be remembered that in the present study, all 
of the ADSD patients were initial injectees. Because BT 
treatment is ongoing, it is possible that long term response 
to the treatment across multiple injections may vary from 
those demonstrated after initial injection. On the one hand, 
it is possible that older voices may improve with long term 
treatment. This may result from ongoing modiﬁ  cation of 
dosage and injection site (Blitzer et al 1998) or from a 
long-term improving trend that has been noted in some 
longitudinal BT studies, the mechanism of which remains 
unclear (Mehta et al 2001; Salvatore et al 2007). Long-term 
improvement may explain the discrepancy in self-report by 
older patients with ADSD exhibited between (Lundy et al 
1998), who examined initial injectees, versus (Wingate et al 
2005) who examined patients who had undergone multiple 
injections. On the other hand, it is possible that older 
ADSD voices may deteriorate even further with long term 
botulinum toxin treatment. There is potential for increased 
tendency to develop immunological response by building 
up of antibodies to BT. Though this has been shown to 
occur in about 3% of BT users who were injected for more 
traditional use in facial cosmetic applications (Zuber et al 
1993). To the best of our knowledge, no data are available 
about antibody production in the elderly as a treatment 
group or in the larynx as a target organ for BT. Further 
longitudinal study across repeated injections is needed to 
address this issue.
Although the age related findings in the present 
retrospective study could not be explained away on the basis of 
potentially confounding factors such as dosage, injection site, 
or days post injection at recording, these remain signiﬁ  cant 
clinical variables that should be more systematically controlled 
in a future prospective replication. This will be particularly 
important for longitudinal research, wherein there is typically 
some degree of “trial and error” modiﬁ  cation of dosage and 
injection site during ongoing re-injections. A more narrow 
time widow for post injection recordings or use of multiple 
time windows will also be desirable to minimize variability 
due to inter-individual recovery rates.
Finally, the limitations of perceptual voice analysis 
should be recognized. The ﬁ  nal output that is radiated from 
the oral cavity of a speaker reﬂ  ects a variety of laryngeal 
and supralaryngeal sources and mechanisms. Moreover, 
even relatively reliable expert listeners bring a certain 
degree or subjectivity and uncertainty to the listening 
experience. Thus it is possible that other measures, 
including acoustic, physiological and patient self-rating 
instruments may reveal changes in older patients with 
ADSD that were not captured by the perceptual methods, 
however rigorous, employed in the present study. Future 
studies comparing older and younger speakers with 
ADSD and their response to BT treatment should include 
a combination of perceptual, acoustic, physiological (eg, 
laryngeal resistance and airﬂ  ow measures), in conjunction 
with patient self-reports.Clinical Interventions in Aging 2008:3(1) 149
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